德国Merk对EGFR/MUC1 ADC的介绍中,强调了通过双靶点定位提高特异性降低副作用,同时协同结合增加肿瘤内化率增强毒素作用的设计思路。 图3 德国默克EGFR/MUC1 ADC(来源:公开资料) 阿斯利康的EGFR/cMet双抗ADCAZD9592,通过可切割Linker将抗体与TOP1i载荷AZ14170132偶联,相较于EGFR,AZD9592对cMet具有更高的亲和力(>15 ...
德国Merk对EGFR/MUC1 ADC的介绍中,强调了通过双靶点定位提高特异性降低副作用,同时协同结合增加肿瘤内化率增强毒素作用的设计思路。 图3 德国默克EGFR/MUC1 ADC(来源:公开资料) 阿斯利康的EGFR/cMet双抗ADCAZD9592,通过可切割Linker将抗体与TOP1i载荷AZ14170132偶联,相较于EGFR,AZD9592对cMet具有更高的亲和力(>15 ...
5、BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity 编号: 6325 场次: Anticancer Immunotherapeutics 展示时间: April 19, 2023, 9:00 AM – 12:30 PM 简介:BSA01是一款EGFR x MUC1全人双抗ADC药物,其中MUC1端抗体...
思道医药(Xadcera)目前已经注资落地在苏州BioBAY。公司英文名中的"X"代表Cross或是Bispecific, "adc"表示公司以开发ADC为主要战略目标,"era"取自治疗therapy。思道医药致力于开发全球有竞争力的双抗ADC药物管线,造福人类健康。 思道医药目前已经从百奥赛图引进3条双抗ADC管线,均处于临床前阶段。预计于2024年1月启...
Provided are immunoconjugates comprising bispecific anti-MUC 1/EGFR antibodies conjugated to hemiasterlin-based moieties via cleavable linkers, and pharmaceutical compositions thereof. Provided also are methods of treating cancer using such immunoconjugates and pharmaceutical compositions.KNUEHL, CHRISTINE...
directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589)....
今年的AACR会议上,百奥赛图带来了多款临床前双抗ADC的进展,包括靶向5T4 × MUC1的双抗ADC药物BCG016、PTK7 × EGFR双抗ADC药物BCG017和EGFR × HER3双抗ADC药物BCG019,它们在临床前都显示良好的抗肿瘤活性。 03小结 双抗ADC因融合了ADC和双抗的优点,有望克服ADC引起耐药等问题而备受关注,百利天恒的BL-B01...
The present invention relates to a pharmaceutical composition comprising a bispecific anti-MUC1/EGFR antibody-drug conjugate (EGFR x MUC1 - Hemiasterlin bispecific antibody-drug conjugate (ADC)), a polyoxyethylene-polyoxypropylene block copolymer and a buffer, particularly a pharmaceutical preparation ...
bispecific antibodybreast cancersurfaceomeEGFRMUC1Breast cancer (BC) treatment has traditionally been challenging due to tumor heterogeneity. Bispecific antibodies (bsAbs) offer a promising approach for overcoming these challenges by targeting multiple specific epitopes. In the current study, we designed a...